Research programme: cancer therapeutics - LIDDS/Belina Pharma

Drug Profile

Research programme: cancer therapeutics - LIDDS/Belina Pharma

Latest Information Update: 25 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Belina Pharma; LIDDS
  • Class Antineoplastics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer

Most Recent Events

  • 30 Jun 2017 LIDDS has patent protection for its NanoZolid® technology
  • 11 Apr 2017 LIDDS and Belina Pharma agree to co-develop cancer therapeutic
  • 11 Apr 2017 Early research in Breast cancer in Sweden (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top